ES3048983T3 - A plurality of tasquinimod particles and use thereof - Google Patents

A plurality of tasquinimod particles and use thereof

Info

Publication number
ES3048983T3
ES3048983T3 ES22730773T ES22730773T ES3048983T3 ES 3048983 T3 ES3048983 T3 ES 3048983T3 ES 22730773 T ES22730773 T ES 22730773T ES 22730773 T ES22730773 T ES 22730773T ES 3048983 T3 ES3048983 T3 ES 3048983T3
Authority
ES
Spain
Prior art keywords
particles
interval
tasquinimod
cancer
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22730773T
Other languages
English (en)
Spanish (es)
Inventor
Hans WÄNNMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Application granted granted Critical
Publication of ES3048983T3 publication Critical patent/ES3048983T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Powder Metallurgy (AREA)
ES22730773T 2021-05-25 2022-05-23 A plurality of tasquinimod particles and use thereof Active ES3048983T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21175623 2021-05-25
PCT/EP2022/063887 WO2022248401A1 (en) 2021-05-25 2022-05-23 A plurality of tasquinimod particles and use thereof

Publications (1)

Publication Number Publication Date
ES3048983T3 true ES3048983T3 (en) 2025-12-12

Family

ID=76098832

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22730773T Active ES3048983T3 (en) 2021-05-25 2022-05-23 A plurality of tasquinimod particles and use thereof

Country Status (14)

Country Link
US (2) US12485095B2 (enExample)
EP (1) EP4346773B1 (enExample)
JP (1) JP7874664B2 (enExample)
KR (1) KR20240012436A (enExample)
CN (1) CN117295492A (enExample)
AU (1) AU2022281056A1 (enExample)
BR (1) BR112023023715A2 (enExample)
CA (1) CA3218977A1 (enExample)
ES (1) ES3048983T3 (enExample)
IL (1) IL308542A (enExample)
MX (1) MX2023013301A (enExample)
PL (1) PL4346773T3 (enExample)
WO (1) WO2022248401A1 (enExample)
ZA (1) ZA202311594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025228998A1 (en) * 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
CN104016951B (zh) * 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
WO2012004338A1 (en) 2010-07-09 2012-01-12 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
WO2015160696A1 (en) 2014-04-14 2015-10-22 Yale University Compositions and methods of inhibiting histone deacetylases
EP3041472B1 (en) 2014-09-23 2017-02-01 Active Biotech AB Quinoline carboxamides for use in the treatment of multiple myeloma
BR112017009854B1 (pt) * 2014-11-19 2022-08-23 Active Biotech Ab Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
WO2018208993A1 (en) * 2017-05-09 2018-11-15 Dignity Health Drug delivery composition and method of fabrication
US20230293512A1 (en) 2020-07-23 2023-09-21 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
WO2022152902A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Also Published As

Publication number Publication date
EP4346773B1 (en) 2025-07-02
US20260076908A1 (en) 2026-03-19
ZA202311594B (en) 2025-04-30
JP7874664B2 (ja) 2026-06-16
US20240285532A1 (en) 2024-08-29
KR20240012436A (ko) 2024-01-29
JP2024520307A (ja) 2024-05-24
BR112023023715A2 (pt) 2024-02-20
PL4346773T3 (pl) 2025-11-03
MX2023013301A (es) 2023-12-04
AU2022281056A1 (en) 2023-11-30
IL308542A (en) 2024-01-01
EP4346773C0 (en) 2025-07-02
US12485095B2 (en) 2025-12-02
EP4346773A1 (en) 2024-04-10
CN117295492A (zh) 2023-12-26
WO2022248401A1 (en) 2022-12-01
CA3218977A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
ES2951547T3 (es) Composiciones farmacéuticas que comprenden nilotinib
ES2435816T3 (es) Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual
ES2748432T3 (es) Composiciones farmacéuticas que comprenden un modulador de S1P
ES2645008T3 (es) Formas de dosificación sólida de bendamustina
ES2794018T3 (es) Composiciones sólidas que comprenden un activador de la glucoquinasa y métodos para crearlas y usarlas
PT85353B (pt) Processo de preparacao de composicoes farmaceuticas de libertacao controlada e de matriz a base de alcool alifatico e resina acrilica
KR102598782B1 (ko) 알펠리십을 포함하는 제약 조성물
ES2610966T3 (es) Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol
ES2977279T3 (es) Nuevas formulaciones de 4-cloro-N-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida
JP2017521442A (ja) がんを処置するための組み合わせ
ES2870562T3 (es) Composiciones y procedimientos para el tratamiento del crecimiento celular anormal
US11266649B2 (en) Pharmaceutical formulations
US20260076908A1 (en) Plurality of tasquinimod particles and use thereof
Krishna et al. Strategic approaches and evaluation of gastro retentive drug delivery system-A Review
BR112020000207A2 (pt) composição farmacêutica de forma de dosagem oral de enzalutamida e processo para preparar a composição farmacêutica de forma de dosagem oral de enzalutamida
CN114555082B (zh) 包含埃索美拉唑及碳酸氢钠的稳定的药剂学组合物
HK40107035A (en) A plurality of tasquinimod particles and use thereof
HK40107035B (en) A plurality of tasquinimod particles and use thereof
KR20240105511A (ko) 저용량, 고약물 노출량의 소라페닙 또는 도나페닙 경구제 및 그 응용
BR112019016400A2 (pt) composições de complexos de gálio (iii) para administração oral
BR112020006599A2 (pt) composições e métodos de uso de cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carboxamida
CN112770731A (zh) 以4’-硫代核苷类化合物为活性成分的口服药物组合物、其制备方法及其用途
BR102012027409B1 (pt) composição farmacêutica e seu método de preparo
EA040951B1 (ru) Лекарственные формы цис-4-[2-{[(3s,4r)-3-фтороксан-4-ил]амино}-8-(2,4,6-трихлоранилино)-9н-пурин-9-ил]-1-метилциклогексан-1-карбоксамида и их применение в способе лечения рака